Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention [Original Articles]

Conclusions:
Implementing CYP2C19 genotype–guided DAPT is feasible and sustainable in a real-world setting but challenging to maintain at a consistently high level of fidelity. The higher risk of major adverse cardiovascular or cerebrovascular associated with clopidogrel use in CYP2C19 LOF allele carriers suggests that use of genotype-guided DAPT in practice may improve clinical outcomes.

Source: Circulation: Cardiovascular Genetics - April 3, 2018 Category: Cardiology Authors: Lee, C. R., Sriramoju, V. B., Cervantes, A., Howell, L. A., Varunok, N., Madan, S., Hamrick, K., Polasek, M. J., Lee, J. A., Clarke, M., Cicci, J. D., Weck, K. E., Stouffer, G. A. Tags: Genetics, Pharmacology, Acute Coronary Syndromes, Atherosclerosis Original Articles Source Type: research